{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:02:36Z","timestamp":1791417756521,"version":"4.3.3"},"reference-count":64,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,6,27]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>In patients with MPNs, repression of MIRlet-7 and mutations in the polycomb genes EZH2 and ASXL1 correlate with HMGA2 overexpression. Hmga2 overexpression collaborates with JAK2V617F to promote lethal MPN in mice, highlighting the crucial role of Hmga2.<\/jats:p>","DOI":"10.1182\/bloodadvances.2017004457","type":"journal-article","created":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T20:50:18Z","timestamp":1497473418000},"page":"1001-1015","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms"],"prefix":"10.1182","volume":"1","author":[{"given":"Koki","family":"Ueda","sequence":"first","affiliation":[{"name":"Department of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Hematology,"},{"name":"Department of Blood Transfusion and Transplantation Immunology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[{"name":"Department of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayo","family":"Harada-Shirado","sequence":"additional","affiliation":[{"name":"Department of Hematology,"},{"name":"Department of Blood Transfusion and Transplantation Immunology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuei","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ohkawara","sequence":"additional","affiliation":[{"name":"Department of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Shichishima-Nakamura","sequence":"additional","affiliation":[{"name":"Department of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Shikama","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Fukushima Medical University, Fukushima, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Human Lifesciences, Fukushima Medical University School of Nursing, Fukushima, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Mason","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Children\u2019s Hospital of Philadelphia, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bessler","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Children\u2019s Hospital of Philadelphia, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soji","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Shide","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Koide","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Aoyama","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiko","family":"Oshima","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Iwama","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuchika","family":"Takeishi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2017,6,14]]},"reference":[{"issue":"33","key":"2019111611295255700_B1","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1200\/JCO.2004.00.9316","article-title":"Pathogenesis of myelofibrosis with myeloid metaplasia","volume":"23","author":"Tefferi","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111611295255700_B2","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood-2008-03-077966","article-title":"Myeloproliferative disorders","volume":"112","author":"Levine","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111611295255700_B3","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"17","key":"2019111611295255700_B4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"7037","key":"2019111611295255700_B5","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"25","key":"2019111611295255700_B6","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111611295255700_B7","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111611295255700_B8","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111611295255700_B9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"issue":"9","key":"2019111611295255700_B10","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2009-12-259747","article-title":"JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"issue":"17","key":"2019111611295255700_B11","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111611295255700_B12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","article-title":"Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice","volume":"116","author":"Marty","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111611295255700_B13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.leu.2405043","article-title":"Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F","volume":"22","author":"Shide","year":"2008","journal-title":"Leukemia"},{"issue":"8","key":"2019111611295255700_B14","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"issue":"22","key":"2019111611295255700_B15","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111611295255700_B16","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/leu.2011.77","article-title":"DNMT3A mutations in myeloproliferative neoplasms","volume":"25","author":"Stegelmann","year":"2011","journal-title":"Leukemia"},{"issue":"7","key":"2019111611295255700_B17","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/leu.2011.82","article-title":"DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"issue":"11","key":"2019111611295255700_B18","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/leu.2009.141","article-title":"Mutations of ASXL1 gene in myeloproliferative neoplasms","volume":"23","author":"Carbuccia","year":"2009","journal-title":"Leukemia"},{"issue":"8","key":"2019111611295255700_B19","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"issue":"4","key":"2019111611295255700_B20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/bjh.12276","article-title":"MicroRNAs in myeloproliferative neoplasms","volume":"161","author":"Zhan","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111611295255700_B21","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/bjh.13129","article-title":"Dysregulation of the MIRLET7\/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms","volume":"168","author":"Harada-Shirado","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111611295255700_B22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1634\/stemcells.2006-0351","article-title":"Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms\u2019 tumor gene 1 (WT1)","volume":"25","author":"Guglielmelli","year":"2007","journal-title":"Stem Cells"},{"issue":"16","key":"2019111611295255700_B23","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"5818","key":"2019111611295255700_B24","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1126\/science.1137999","article-title":"Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation","volume":"315","author":"Mayr","year":"2007","journal-title":"Science"},{"issue":"22","key":"2019111611295255700_B25","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1182\/blood-2011-02-334425","article-title":"3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice","volume":"117","author":"Ikeda","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111611295255700_B26","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1084\/jem.20111709","article-title":"Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes","volume":"209","author":"Oguro","year":"2012","journal-title":"J Exp Med"},{"issue":"8","key":"2019111611295255700_B27","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1084\/jem.20151121","article-title":"The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition","volume":"213","author":"Sashida","year":"2016","journal-title":"J Exp Med"},{"issue":"8","key":"2019111611295255700_B28","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20151136","article-title":"Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis","volume":"213","author":"Shimizu","year":"2016","journal-title":"J Exp Med"},{"issue":"26","key":"2019111611295255700_B29","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1182\/blood-2015-11-679431","article-title":"Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm","volume":"127","author":"Yang","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2019111611295255700_B30","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/ncb2783","article-title":"The Lin28b-let-7-Hmga2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells","volume":"15","author":"Copley","year":"2013","journal-title":"Nat Cell Biol"},{"issue":"12","key":"2019111611295255700_B31","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nrc2271","article-title":"Roles of HMGA proteins in cancer","volume":"7","author":"Fusco","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2019111611295255700_B32","first-page":"15","article-title":"High mobility group a proteins as tumor markers","volume":"2","author":"Pallante","year":"2015","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"2019111611295255700_B33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/gcc.10297","article-title":"Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia","volume":"39","author":"Andrieux","year":"2004","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"2019111611295255700_B34","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1182\/blood-2014-04-555508","article-title":"Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator","volume":"125","author":"Kameda","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111611295255700_B35","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.neuron.2009.08.021","article-title":"Polycomb limits the neurogenic competence of neural precursor cells to promote astrogenic fate transition","volume":"63","author":"Hirabayashi","year":"2009","journal-title":"Neuron"},{"issue":"6543","key":"2019111611295255700_B36","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/376771a0","article-title":"Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C","volume":"376","author":"Zhou","year":"1995","journal-title":"Nature"},{"issue":"5","key":"2019111611295255700_B37","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111611295255700_B38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s12185-014-1567-1","article-title":"JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan","volume":"99","author":"Edahiro","year":"2014","journal-title":"Int J Hematol"},{"issue":"8","key":"2019111611295255700_B39","doi-asserted-by":"crossref","first-page":"e104958","DOI":"10.1371\/journal.pone.0104958","article-title":"Detection of MPLW515L\/K mutations and determination of allele frequencies with a single-tube PCR assay [published correction appears in PLoS One. 2015;10(4):e0124208]","volume":"9","author":"Takei","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"2019111611295255700_B40","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.3324\/haematol.2014.115113","article-title":"JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms","volume":"100","author":"Shirane","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"2019111611295255700_B41","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.4049\/jimmunol.1600622","article-title":"Mechanisms of impaired neutrophil migration by microRNAs in myelodysplastic syndromes","volume":"198","author":"Cao","year":"2017","journal-title":"J Immunol"},{"issue":"3","key":"2019111611295255700_B42","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov"},{"issue":"3","key":"2019111611295255700_B43","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.cell.2006.05.052","article-title":"A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation","volume":"126","author":"Narita","year":"2006","journal-title":"Cell"},{"issue":"12","key":"2019111611295255700_B44","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1084\/jem.20131144","article-title":"Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders","volume":"210","author":"Muto","year":"2013","journal-title":"J Exp Med"},{"issue":"8","key":"2019111611295255700_B45","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/ng.188","article-title":"Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects","volume":"40","author":"McGowan","year":"2008","journal-title":"Nat Genet"},{"issue":"9","key":"2019111611295255700_B46","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1182\/blood-2010-07-295238","article-title":"Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells","volume":"117","author":"Dutt","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111611295255700_B47","doi-asserted-by":"crossref","first-page":"e0152263","DOI":"10.1371\/journal.pone.0152263","article-title":"Mice with a mutation in the Mdm2 gene that interferes with MDM2\/ribosomal protein binding develop a defect in erythropoiesis","volume":"11","author":"Kamio","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"2019111611295255700_B48","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1084\/jem.20131371","article-title":"Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F","volume":"211","author":"Lundberg","year":"2014","journal-title":"J Exp Med"},{"issue":"8","key":"2019111611295255700_B49","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2013-04-498956","article-title":"JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN\u03b1","volume":"122","author":"Hasan","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111611295255700_B50","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2010-06-287318","article-title":"JAK2 impairs stem cell function?","volume":"116","author":"Skoda","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111611295255700_B51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2141.1994.tb04970.x","article-title":"Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis","volume":"88","author":"Martyr\u00e9","year":"1994","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111611295255700_B52","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/ajcp\/103.5.574","article-title":"Deposition of transforming growth factor-beta in the marrow in myelofibrosis, and the intracellular localization and secretion of TGF-beta by leukemic cells","volume":"103","author":"Johnston","year":"1995","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"2019111611295255700_B53","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood-2004-04-1320","article-title":"A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis","volume":"105","author":"Vannucchi","year":"2005","journal-title":"Blood"},{"issue":"8","key":"2019111611295255700_B54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s12032-014-0099-0","article-title":"LMO1 is a novel oncogene in lung cancer, and its overexpression is a new predictive marker for anti-EGFR therapy","volume":"31","author":"Zhang","year":"2014","journal-title":"Med Oncol"},{"issue":"8","key":"2019111611295255700_B55","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.1007\/s13277-014-2066-y","article-title":"LMO1 is a novel oncogene in colorectal cancer and its overexpression is a new predictive marker for anti-EGFR therapy","volume":"35","author":"Liu","year":"2014","journal-title":"Tumour Biol"},{"issue":"7582","key":"2019111611295255700_B56","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nature15540","article-title":"Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism","volume":"528","author":"Oldridge","year":"2015","journal-title":"Nature"},{"issue":"1","key":"2019111611295255700_B57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.devcel.2004.10.019","article-title":"Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA","volume":"8","author":"Zhang","year":"2005","journal-title":"Dev Cell"},{"issue":"14","key":"2019111611295255700_B58","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"5872","key":"2019111611295255700_B59","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.1154040","article-title":"Selective blockade of microRNA processing by Lin28","volume":"320","author":"Viswanathan","year":"2008","journal-title":"Science"},{"issue":"7","key":"2019111611295255700_B60","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ng.392","article-title":"Lin28 promotes transformation and is associated with advanced human malignancies","volume":"41","author":"Viswanathan","year":"2009","journal-title":"Nat Genet"},{"issue":"4","key":"2019111611295255700_B61","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.exphem.2015.12.009","article-title":"Ezh2 regulates the Lin28\/let-7 pathway to restrict activation of fetal gene signature in adult hematopoietic stem cells","volume":"44","author":"Oshima","year":"2016","journal-title":"Exp Hematol"},{"issue":"4","key":"2019111611295255700_B62","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1158\/0008-5472.CAN-06-4074","article-title":"The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function","volume":"67","author":"Brueckner","year":"2007","journal-title":"Cancer Res"},{"issue":"21","key":"2019111611295255700_B63","doi-asserted-by":"crossref","first-page":"10117","DOI":"10.1158\/0008-5472.CAN-07-2544","article-title":"Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis","volume":"67","author":"Lu","year":"2007","journal-title":"Cancer Res"},{"issue":"13","key":"2019111611295255700_B64","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1128\/MCB.01836-08","article-title":"The NF90-NF45 complex functions as a negative regulator in the microRNA processing pathway","volume":"29","author":"Sakamoto","year":"2009","journal-title":"Mol Cell Biol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/15\/1001\/878552\/advances004457.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/15\/1001\/878552\/advances004457.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T11:30:15Z","timestamp":1573903815000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/1\/15\/1001\/15734\/Hmga2-collaborates-with-JAK2V617F-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,14]]},"references-count":64,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2017,6,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2017004457","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,14]]}}}